Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: A systematic review and meta-analysis of randomised, controlled trials

Internal Medicine Journal

Volumn 42, Issue 12, 2012, Pages 1297-1309

  Jiang, L ^a   Yang, K H ^a   Guan, Q L ^a   Mi, D H ^a,b   Wang, J ^a  

^a LANZHOU UNIVERSITY   (China)

^b Second Hospital of Gansu Province   (China)

Author keywords

Cisplatin; Extensive stage small cell lung cancer; Irinotecan; Meta analysis; Platinum

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; PACLITAXEL; TOPOTECAN;

ADVERSE OUTCOME; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CARDIOTOXICITY; COMPARATIVE STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CISPLATIN; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; EPIRUBICIN; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84871379148     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2012.02821.x     Document Type: Article

References (48)

1. European age-standardised rates calculated by the Statistical Information Team at Cancer Research UK, 2011 using data from GLOBOCAN 2008 v1.2, IARC [cited 2010 Aug 8]. Available from URL: http://globocan.iarc.fr
2. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005; 366: 1385-1396.
3. Carney DN. Prophylactic cranial irradiation and small-cell lung cancer. N Engl J Med 1999; 341: 524-526.
4. Amarasena IU, Walters JA, Wood-Baker R, Fong K. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev 2008; CD006849.
5. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327: 1434-1441.
6. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 1996; 348: 563-566.
7. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A etal. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539-4544.
8. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions 5.0.0 [updated February 2008]. In: The Cochrane Collaboration. London: John Wiley & Sons; 2008; 61-62.
9. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
10. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
11. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
13. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
14. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-1900.
15. Clinical Research Center for Solid Tumor, Korea. A study comparing etoposide/cisplatin with irinotecan/cisplatin to treat extensive disease small lung cancer. NLM Identifier NCT 00349492 [cited 2010 Aug 8]. Available from URL: http://clinicaltrials.gov
16. GlaxoSmithKline. Topotecan/etoposide versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive disease-small cell lung cancer. NLM Identifier NCT 00320359 [cited 2010 Aug 8]. Available from URL: http://clinicaltrials.gov
17. Eastern Cooperative Oncology Group. Cisplatin and etoposide phosphate with or without GDC-0449 or cixutumumab in treating patients with extensive-stage small cell lung cancer. NLM Identifier NCT 0887159 [cited 2010 Aug 8]. Available from URL: http://clinicaltrials.gov
18. Anonymous. Cisplatin plus etoposide with or without paclitaxel in treating patients with extensive-stage small cell lung cancer. NLM Identifier NCT00003299 [cited 2010 Aug 8]. Available from URL: http://clinicaltrials.gov
19. European Lung Cancer Working Party. Randomized study of cisplatin-etoposide versus an etoposide regimen without cisplatin in extensive small-cell lung cancer. NLM Identifier NCT 0065858 [cited 2010 Aug 8]. Available from URL: http://clinicaltrials.gov
20. Pfizer CT. Study of irinotecan hydrochloride (Campto(R)) and cisplatin versus etoposide and cisplatin in small cell lung cancer. NLM Identifier NCT 00143455 [cited 2010 Aug 8]. Available from URL: http://clinicaltrials.gov
21. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A etal. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91.
22. Pan D, Hou M, Li H, Yu P, Liu J. Irinotecan plus cisplatin compared with etoposide plus cisplatin for small cell lung cancer: a randomized clinical trial. Chin J Lung Cancer 2006; 9: 443-446.
23. Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr., Beck T etal. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24: 2038-2043.
24. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE etal. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27: 2530-2535.
25. Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X etal. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010; 9: 1810-1816.
26. Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T etal. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007; 97: 162-169.
27. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P etal. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994; 5: 601-607.
28. Lee SM, James LE, Qian W, Spiro S, Eisen T, Gower NH etal. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax 2009; 64: 75-80.
29. Pujol JL, Daures JP, Riviere A, Quoix E, Westeel V, Quantin X etal. Etoposide plus cisplatin with or without the combination of epirubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001; 93: 300-308.
30. Niell HB, Herndon JE 2nd, Miller AA, Watson DM, Sandler AB, Kelly K etal. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005; 23: 3752-3759.
31. Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE etal. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006; 24: 2044-2051.
32. Loehrer PJ, Sr, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A etal. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995; 13: 2594-2599.
33. Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C etal. A multicenter randomized clinical trial comparing paclitaxel-cisplatinetoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001; 12: 463-470.
34. Wilcox RA, Djulbegovic B, Moffitt HL, Guyatt GH, Montori VM. Randomized trials in oncology stopped early for benefit. J Clin Oncol 2008; 26: 18-19.
35. Jiang L, Yang KH, Mi DH, Liu YL, Tian JH, Ma B etal. Safety of irinotecan/cisplatin versus etoposide/ cisplatin for patients with extensive-stage small-cell lung cancer: a meta analysis. Clin Lung Cancer 2007; 8: 497-501.
36. Ihde DC. Small cell lung cancer. State-of-the-art therapy 1994. Chest 1995; 107: 243S-248.
37. Smyth JF. Chemotherapy of small cell lung cancer. Chest 1989; 96: 61S-62.
38. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ etal. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282-291.
39. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999; 17: 1794-1801.
40. Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y etal. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS ONE 2009; 4: e7835.
41. Baka S, Califano R, Ferraldeschi R, Aschroft L, Thatcher N, Taylor P etal. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 2008; 99: 442-447.
42. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF etal. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994; 12: 2022-2034.
43. Beganovic S, Niell HB, Richey S, Wan J. Meta-analysis of dose/cycle of etoposide (VP-16) and cisplatin (DDP) and outcome of patients with extensive small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 2003; 22 (abstract 2662).
44. Maksymiuk AW, Jett JR, Earle JD, Su JQ, Diegert FA, Mailliard JA etal. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol 1994; 12: 70-76.
45. Pignon JP, Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet Oncol 2001; 2: 475-482.
46. Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren Jr. etal. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009; 27: 6006-6011.
47. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L etal. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009; 20: 1674-1681.
48. Papadimitrakopoulou V, Blumenschein GR, Leighl NB, Bennouna J, Soria JC, Burris HA etal. A phase 1/2 study investigating the combination of RAD001(R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): phase 1 results. J Clin Oncol 2008; 22: 20s (abstract 8051).